Three Seasons Wealth LLC Takes $573,000 Position in Procter & Gamble Company (The) $PG

Three Seasons Wealth LLC acquired a new stake in shares of Procter & Gamble Company (The) (NYSE:PG) during the 4th quarter, Holdings Channel.com reports. The fund acquired 3,996 shares of the company’s stock, valued at approximately $573,000.

Several other large investors also recently bought and sold shares of PG. Halbert Hargrove Global Advisors LLC bought a new stake in shares of Procter & Gamble in the third quarter worth approximately $25,000. Saranac Partners Ltd bought a new position in Procter & Gamble during the third quarter valued at approximately $30,000. Corundum Trust Company INC purchased a new stake in Procter & Gamble in the third quarter worth approximately $32,000. Caitlin John LLC purchased a new stake in Procter & Gamble in the third quarter worth approximately $34,000. Finally, Marquette Asset Management LLC bought a new stake in Procter & Gamble in the 3rd quarter worth approximately $37,000. 65.77% of the stock is currently owned by institutional investors.

Procter & Gamble Trading Down 0.2%

Procter & Gamble stock opened at $144.44 on Wednesday. Procter & Gamble Company has a 12-month low of $137.62 and a 12-month high of $174.80. The firm has a market capitalization of $335.67 billion, a price-to-earnings ratio of 21.40, a P/E/G ratio of 4.84 and a beta of 0.37. The firm has a 50 day moving average of $153.88 and a 200 day moving average of $149.88. The company has a current ratio of 0.72, a quick ratio of 0.51 and a debt-to-equity ratio of 0.49.

Procter & Gamble (NYSE:PG) last posted its quarterly earnings results on Friday, January 23rd. The company reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.02. The business had revenue of $22.21 billion during the quarter, compared to analyst estimates of $22.36 billion. Procter & Gamble had a net margin of 19.30% and a return on equity of 32.21%. The company’s revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.88 earnings per share. As a group, research analysts predict that Procter & Gamble Company will post 6.91 earnings per share for the current year.

Procter & Gamble Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, February 17th. Investors of record on Friday, January 23rd were issued a $1.0568 dividend. The ex-dividend date of this dividend was Friday, January 23rd. This represents a $4.23 annualized dividend and a yield of 2.9%. Procter & Gamble’s dividend payout ratio is currently 62.52%.

Insiders Place Their Bets

In other Procter & Gamble news, CEO Ma. Fatima Francisco sold 5,549 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $165.29, for a total transaction of $917,194.21. Following the sale, the chief executive officer directly owned 1,029 shares of the company’s stock, valued at $170,083.41. This trade represents a 84.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Jon R. Moeller sold 162,232 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $162.45, for a total value of $26,354,588.40. Following the completion of the transaction, the chairman owned 319,385 shares in the company, valued at $51,884,093.25. The trade was a 33.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 348,618 shares of company stock worth $55,462,643 in the last three months. 0.20% of the stock is owned by company insiders.

More Procter & Gamble News

Here are the key news stories impacting Procter & Gamble this week:

• Positive Sentiment: OLAY peptide research — New clinical and mechanistic data presented for OLAY highlight proprietary peptide technology and cell‑adhesion targets that P&G plans to move rapidly into formulations; successful commercialization could bolster pricing power and organic growth for a core beauty brand. OLAY Peptide Research Puts New Spotlight On Procter And Gamble Valuation
• Positive Sentiment: Analysts remain constructive in places — coverage notes that P&G can fare better than peers amid sluggish consumer sentiment, supporting the view of PG as a relatively defensive consumer staples holding. Analysts Constructive on The Procter & Gamble (PG) Amid Sluggish Consumer Sentiment
• Neutral Sentiment: Recent trading strength — PG ticked higher while the broader market fell on 3/30, showing relative strength that may reflect defensive demand; however this was a short‑term move rather than new fundamental news. Procter & Gamble (PG) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Q4 results mixed — Q4 EPS slightly beat estimates (+$0.02) while revenue marginally missed; steady margins and cash flow help the case for the dividend and buybacks, but top‑line softness tempers upside. (Earnings detail from recent company report.)
• Neutral Sentiment: Deutsche Bank trimmed its price target (from $171 to $162) but kept a Hold — this narrows upside but is not a sell signal; investors should weigh this against other analyst views. Deutsche Bank Lowers Price Target on PG
• Neutral Sentiment: Unrelated retailer weakness — a separate report on RH’s weak quarter is unlikely to directly affect PG but signals broader discretionary‑spending challenges in retail. RH (RH) Lags Q4 Earnings and Revenue Estimates
• Negative Sentiment: TD Cowen cut its price target to $142 (from $156) and kept a Hold, citing oil‑linked input cost inflation tied to the Iran war that it believes P&G cannot fully absorb — this is the main near‑term headwind pressuring the stock. Wall Street Downgrades Procter & Gamble Amid Iran War Cost Pressures and More

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Barclays set a $155.00 price target on Procter & Gamble in a report on Friday, January 16th. JPMorgan Chase & Co. upgraded Procter & Gamble from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $157.00 to $165.00 in a research report on Friday, January 23rd. TD Cowen downgraded Procter & Gamble from a “buy” rating to a “hold” rating and increased their target price for the company from $150.00 to $156.00 in a report on Tuesday, January 27th. BNP Paribas Exane dropped their target price on Procter & Gamble from $172.00 to $164.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Finally, Rothschild & Co Redburn boosted their price target on Procter & Gamble from $155.00 to $157.00 and gave the company a “neutral” rating in a research note on Friday, January 23rd. Twelve research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $167.83.

Procter & Gamble Profile

Procter & Gamble (NYSE: PG) is a multinational consumer goods company headquartered in Cincinnati, Ohio. Founded in 1837 by William Procter and James Gamble, P&G has grown into one of the world’s largest producers of branded consumer packaged goods. The company focuses on developing, manufacturing and marketing a broad portfolio of household and personal care products sold to consumers and retailers worldwide.

P&G’s product offering spans several core business categories, including Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care.